Clean Science Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹220Cr
- −8.7% YoY
- −10.2% QoQ
- Net profit
- ₹46Cr
- −30.3% YoY
- −16.4% QoQ
- Margin
- 33%
- −8 pp YoY
- −3 pp QoQ
Guidance rank: #55 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Performance Chemical 1 plant started producing in-house hydroquinone and catechol; sales to start from February with growth expected in March FY '27. The company anticipates margin improvement and revenue growth by launching new products and maintaining disciplined capex cycles.
From Clean Science's Q3 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Performance Chemical 1 plant started producing in-house hydroquinone and catechol; sales to start from February with growth expected in March FY '27.
- Performance Chemical 2 plant commissioning delayed to May-June FY '27; revenue generation anticipated from Q4 FY '27.
- HALS business showing strong growth, with 55% Y-o-Y volume increase; expected to sustain momentum in coming years.
- New product commercialization (hydroquinone and catechol) will lower raw material costs and enhance margins.
- Efforts ongoing to improve process efficiencies and bring more products online, aiming for volume growth and margin improvement.
- Domestic and international demand expected to recover post current macroeconomic challenges.
- Trade deal with Europe starting in FY '27 to potentially reduce tariffs (5.5%-12%), helping competitiveness against China.
2 more points from Clean Science's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Clean Science said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Hydroquinone and catechol plants were commercialized in December; customer trials ongoing.
- Capex for Performance Chemical 2 is on plan; commercialization expected in Q1 FY '27 (around May-June).
- Performance Chemical 2 will start generating staggered revenues from Q4 FY '27.
- Performance Chemical 1 running at ~80% capacity utilization; expected revenue INR 260 crores in FY '27 (down from earlier estimate of INR 320 crores) due to reduced prices.
- Capex investments amount to around INR 1.5 billion each for Performance Chemical 1 and 2.
- The expansion of TBHQ and in-house production of hydroquinone expected to moderate raw material costs and improve margins.
2 more points from Clean Science's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Clean Science said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Clean Science said on order book & pipeline — free account, 30 seconds.
Clean Science — Quarterly revenue & net profit
Clean Science Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 220 | 241 | -8.7% | 245 | -10.2% |
| Operating profit (EBITDA) | 72 | 98 | -26.5% | 87 | -17.2% |
| Operating margin | 33% | 41% | -8 pp | 36% | -3 pp |
| Profit before tax | 63 | 85 | -25.9% | 75 | -16% |
| Net profit (PAT) | 46 | 66 | -30.3% | 55 | -16.4% |
| EPS (₹) | 4.32 | 6.18 | -30.1% | 5.22 | -17.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹299 Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Clean Science's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- IVP (Q3 FY26)
Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector
- Gujarat Alkalies (Q3 FY26)
3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Clean Science and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Clean Science Q3 FY26 results?
Performance Chemical 1 plant started producing in-house hydroquinone and catechol; sales to start from February with growth expected in March FY '27. The company anticipates margin improvement and revenue growth by launching new products and maintaining disciplined capex cycles.
What is Clean Science share price analysis?
Clean Science currently shows a neutral. The stock trades at a P/E of 37.7 with a market cap of ₹8,774 Cr. Investors should review the full earnings analysis for detailed insights.
Is Clean Science planning capital expenditure?
Hydroquinone and catechol plants were commercialized in December; customer trials ongoing.
Keep Clean Science on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
